Silicon Valley has brought us computer hardware and software that has changed our lives, social media companies that help us to connect, and wearable gadgetry to improve our workouts, if not help us keep time, and now, a product to disrupt dental care: a luxury gel toothpaste called Livionex.
Livionex Inc., a health care start-up focused on biofilms and inflammation, has worked for 12 years with researchers at the University of Texas, Galveston and University of California at Irvine to come up with a substance — activated edathamil — that breaks up the plaque biofilm on teeth, making it harder for plaque to stick to the teeth, even at the gum line and in hard-to-reach places between the teeth.
Plaque buildup can lead to gingivitis or periodontitis, which has been linked to cardiac disease, arthritis and diabetes. Activated edathamil, according to a statement by the company, is not abrasive, detergent or antimicrobial.
The company recently released results of a double-blind clinical trial study on reduction of plaque, gingivitis and gum bleeding. It was conducted at the Beckman Laser Institute of UC Irvine and compared Livionex Dental Gel to Colgate Total, the leading American Dental Association and Food and Drug Administration approved anti-plaque, anti-gingivitis toothpaste.
The results were impressive: A a 260 percent reduction in plaque index, a 229 percent reduction in gingivitis index and a 232 percent reduction in gum bleeding index as compared to Colgate Total. The results were recently published in the journal Lasers in Surgery and Medicine.
If this is not the sort of thing that makes you jump for joy, be assured that dentists around the nation — maybe even yours — are taking note.
Dental pharmacologist Dr. Peter Jacobson said in a statement provided by the company that a product that improves the effectiveness of tooth-brushing to the degree found in the study “is not only a breakthrough, but can be categorized as a disruptive innovation with major public health implications. It redefines what toothpaste and oral hygiene are all about.”
Livionex’s chief executive officer, Amit Goswamy, a Stanford Business School alum, said the results of the study “validates our 10 years of research and development. The Livionex team is excited that the dental gel will pave the way to combat America’s silent epidemic of gingivitis and periodontitis.”